Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1.
about
Modulation, Plasticity and Pathophysiology of the Parallel Fiber-Purkinje Cell Synapse.A positive feedback loop linking enhanced mGluR function and basal calcium in spinocerebellar ataxia type 22013 Philip S. Portoghese Medicinal Chemistry Lectureship: drug discovery targeting allosteric sites.Pharmacological characterization of mGlu1 receptors in cerebellar granule cells reveals biased agonism.Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate ReceptorsTransduction of group I mGluR-mediated synaptic plasticity by β-arrestin2 signalling.Are Type 1 metabotropic glutamate receptors a viable therapeutic target for the treatment of cerebellar ataxia?Cellular and circuit mechanisms underlying spinocerebellar ataxias.Progressive impairment of cerebellar mGluR signalling and its therapeutic potential for cerebellar ataxia in spinocerebellar ataxia type 1 model mice.Type-1 metabotropic glutamate receptor signaling in cerebellar Purkinje cells in health and disease.Re-exploration of the mGlu₁ PAM Ro 07-11401 scaffold: Discovery of analogs with improved CNS penetration despite steep SAR.Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild TypeRelationship between type 1 metabotropic glutamate receptors and cerebellar ataxia.Parallel fiber to Purkinje cell synaptic impairment in a mouse model of spinocerebellar ataxia type 27.New old drug(s) for spinocerebellar ataxias.In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.Purkinje Cell Signaling Deficits in Animal Models of Ataxia.mGlu1 Receptors Monopolize the Synaptic Control of Cerebellar Purkinje Cells by Epigenetically Down-Regulating mGlu5 Receptors
P2860
Q28069538-6262850E-BE18-4635-8E96-BA47840F65A1Q33728850-E03619E0-73A5-4789-B4B8-20E9FBE5AA52Q34243209-4C38C154-8254-4099-9480-9401E79A1788Q35287319-015FE4D4-CCA2-4D34-A4C2-E893034E9C3AQ37183072-1312DBC3-A57A-4416-93E3-FE5A315C43CAQ37464855-0C878A93-F776-4E39-B3A5-94EF9C0657C3Q38691240-FDB3CB27-1B2E-4EA1-A23A-A7C5A93D976FQ38838873-ECEC9D9B-A780-45BA-9361-A92546CEADF7Q38839478-4695BF06-4226-4C49-B8A4-84E7BE3969D4Q39257857-39E82918-E05E-4143-B08E-CF3189CCBF9EQ40237946-760C57A2-1722-4865-AF56-FB1EB9DCDDB6Q40435465-3BDCD551-A44F-4D63-B578-ECFF57AB82B2Q40584019-9B828486-F407-411E-ADA9-E0BB0DE6DE74Q42055747-381D8FA0-A51B-4B1C-823A-B1539BFBF78EQ48107041-622B7CE7-297B-4FED-9745-A308DD469C07Q48825511-698A1D4E-ADF4-4DF9-A80B-10C35DAE07CCQ55097137-A6A2384F-FFE4-43CA-8A8C-9A2098F5CBE5Q58761850-B4E94F00-56F4-4E17-99B8-1F5C12F58DD4
P2860
Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Pharmacological enhancement of ...... spinocerebellar ataxia type 1.
@en
Pharmacological enhancement of ...... spinocerebellar ataxia type 1.
@nl
type
label
Pharmacological enhancement of ...... spinocerebellar ataxia type 1.
@en
Pharmacological enhancement of ...... spinocerebellar ataxia type 1.
@nl
prefLabel
Pharmacological enhancement of ...... spinocerebellar ataxia type 1.
@en
Pharmacological enhancement of ...... spinocerebellar ataxia type 1.
@nl
P2093
P2860
P50
P356
P1433
P1476
Pharmacological enhancement of ...... spinocerebellar ataxia type 1.
@en
P2093
Cristina Zappulla
Giuseppe Battaglia
Luana Lionetto
Maurizio Simmaco
Roberto Gradini
P2860
P2888
P356
10.1186/1756-6606-6-48
P50
P577
2013-11-19T00:00:00Z
P5875
P6179
1017150851